18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

  • STATUS
    Recruiting
  • End date
    Jun 21, 2023
  • participants needed
    12
  • sponsor
    Tulane University
Updated on 21 October 2021
platelet count
renal function
prednisone
testosterone
metastasis
neutrophil count
docetaxel
bone scan
abiraterone
luteinizing hormone
gonadotropin releasing hormone
adenocarcinoma
soft tissue disease
prostate adenocarcinoma

Summary

This is a pilot phase 2 single-arm study, of men with metastatic castration-resistant prostate cancer (mCRPC). Patients will be treated with any of the approved life-prolonging therapies: abiraterone 1000 mg daily plus prednisone 5 mg (or dexamethasone 0.5 mg) daily, enzalutamide 160 mg daily, or docetaxel 50 mg/m2 every two weeks or 75 mg/m2 every three weeks.

Description

Prostate cancer is a hormonally-driven disease and androgens are key in the growth of both normal prostate and prostate cancer cells. Once mCRPC is evident, most patients receive a second-generation hormonal therapy to further suppress the synthesis or androgens (abiraterone) and to block androgen receptor (AR) activation, nuclear translocation and DNA binding (enzalutamide).

Conventional imaging of prostate cancer has limitations in staging, restaging after biochemical relapse, and response assessment. Functional imaging with positron emission tomography (PET) can target various aspects of tumor biology and is clearly superior in the detection of extra-prostatic disease. 18F-fluciclovine is a synthetic amino acid transported across mammalian cell membranes by amino acid transporters that are upregulated in prostate cancer cells.

18F-fluciclovine is approved for PET imaging to identify sites of prostate cancer recurrence in men with rising prostate specific antigen (PSA) following prior definitive treatment. This study describes the changes in 18F-fluciclovine PET scan and compare these results with PSA and conventional computerized tomography (CT) and bone scans, in mCRPC patients treated with abiraterone acetate-prednisone, enzalutamide or docetaxel.

Details
Condition Metastatic Castration Resistant Prostate Cancer
Treatment 18F-fluciclovine PET Scan
Clinical Study IdentifierNCT04158245
SponsorTulane University
Last Modified on21 October 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
Age 18 years
Histologically confirmed adenocarcinoma of the prostate
Ongoing use of luteinizing hormone-releasing hormone (LHRH) required in the absence of surgical castration and castrate concentration of testosterone (< 50 ng/dL)
Detectable PSA of at least 2 ng/dL
Metastatic disease documented by CT or bone scan within 42 days of cycle 1 day 1
Life expectancy of 6 months
Must have disease progression despite a castrate concentration of testosterone of < 50 ng/dL based on
PSA progression defined as increase in PSA of at least 2 ng/dL and 25% from nadir values of prior therapy, determined by 2 separate measurement taken at least 1 week apart
And/or
B. Radiographic disease progression based on response evaluation criteria in
solid tumors (RECIST) 1.1 for soft tissue disease and/or prostate cancer
working group 3 (PCWG3) for bone only disease
\. No prior life-prolonging therapies for mCRPC are allowed, except
Sipuleucel-T
\. The use of docetaxel in the metastatic hormone-sensitive prostate cancer
(mHSPC) setting is allowed
\. Low dose prednisone (10 mg or less) or equivalent is allowed
\. Acceptable liver function (within 28 days from enrollment) defined as
Bilirubin < 2.5 times upper limit of normal (ULN), except for patients with known Gilbert disease (in such cases bilirubin < 5 times ULN)
AST (SGOT) and ALT (SGPT) < 3 times ULN
Acceptable renal function (within 28 days from enrollment)
Serum creatinine 2.0 x ULN or creatinine clearance 30 mL/min
Acceptable hematologic status (within 28 days from enrollment)
Absolute neutrophil count (ANC) 1000 cell/mm3 (100 x 109/L)
Platelet count 100,000 platelet/mm3 (100 x 109/L)
Hemoglobin 9 g/dL
At least 2 weeks since prior radiation before starting study treatment (cycle 1 day 1)
Able to understand and willing to sign a written informed consent document
Patients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 1 week after last dose of abiraterone acetate

Exclusion Criteria

Pathological findings consistent with small cell carcinoma of the prostate
Prior treatment with docetaxel for metastatic castration-resistant prostate cancer (CRPC)
Patient with normal 18F-flucicolovine PET/CT scans at baseline
Know allergies, hypersensitivity, or intolerance to abiraterone, prednisone, 18F-fluciclovine or their excipients
Any chronic medical condition requiring 10 mg daily of systemic prednisone (or equivalent)
Major surgery (e.g., required general anesthesia) within 2 weeks before screening
Uncontrolled active infection (including hepatitis B or C or AIDS). Patients with hepatitis B/C who have disease under control and no significant liver function impairment, and undetectable viral load will be allowed to participate. Similarly, patients with known HIV and 400 CD4 + T cells are allowed to participate
Evidence of other metastatic malignancies within the last year
Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note